Simon Sturge
Chairman at MOONLAKE IMMUNOTHERAPEUTICS
Net worth: 17 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jorge da Silva | M | 47 |
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Catherine Moukheibir | F | 64 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 5 years |
| Kristian Reich | M | 58 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Paulus Stoffels | M | 62 | 2 years | |
| Kara Lassen | M | 45 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Ramnik Xavier | M | 62 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Andrew Phillips | M | 53 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Spike N. Loy | M | 43 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Matthias Bodenstedt | M | 36 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Rory James Swanton Shaw | M | 70 | 5 years | |
| Peter Guenter | M | 61 | 5 years | |
| Jonathan Ronald Kropman | M | 67 |
Weizmann UK
 Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Peter D. Parker | M | 73 |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Adam Michael Denning | M | 53 | 4 years | |
| David Marks | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Thad Huston | M | 54 | 1 years | |
| Lena Elisabeth Svanberg | M | 63 | 4 years | |
| Paul Yaworsky | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 5 years |
| Arnout Ploos van Amstel | M | 60 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Oliver Daltrop | M | 47 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Thomas James Oakley | M | 36 | 5 years | |
| Susanne Antonie Schaffert | M | 57 | 1 years | |
| Helga Rübsamen-Schaeff | M | 75 | 10 years | |
| Jérôme Contamine | M | 66 | 2 years | |
| Philipp Nicholas Andre M. Prince | M | 54 | 4 years | |
| Barry Townsley | M | 77 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Howard Terence Stanton | M | 82 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Linda Higgins | M | 62 | 5 years | |
| Dan Baker | M | 74 | 2 years | |
| Marcus Kuhnert | M | 56 | 10 years | |
| David de Graaf | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Annelies Denecker | F | - | - | |
| Annelies Missotten | F | 52 | 6 years | |
| Maxwell John Nisner | M | 72 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Nicolas Mosimann | M | - | - | |
| Joao Neves | M | - | - | |
| Dragos Budinschi | M | - | - | |
| Laura Matz | F | - | 5 years | |
| Patrícia Isabel Sousa Caldinha | F | - | 2 years | |
| Brian Hubbard | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Phil Dudfield | M | - | - | |
| Nuala Brennan | F | 55 | 3 years | |
| Iris Good | F | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Valeria Cnossen | F | 51 | 2 years | |
| Andrew Dickinson | M | 54 | - | |
| Rozanne Gallon | F | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Rahul Ballal | M | 46 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| John Henry Ritblat | M | 88 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Martin David Paisner | M | 81 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Leslie A. Turnberg | M | 89 |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Marieke Vermeersch | F | - | 3 years | |
| Maina Bhaman | M | 52 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 1 years |
| Lord Mitchell | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Michael Baran | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 3 years |
| Andreas Jurgeit | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
| Matthias J. Heinzel | M | 57 | 5 years | |
| Charles Wolfson Townsley | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Sandra Cauwenberghs | M | - | 4 years | |
| Sofie van Gijsel | F | - | 6 years | |
| Nandita Shangari | M | 43 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 1 years |
| Arabella Duffield | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Michael Sandler | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Benny Chain | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Dean Lush | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Denis Raeburn | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Hayley Sieff | M | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
| Denitza Roussinova | F | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alastair Riddell | M | 74 | 6 years | |
| Stephen Parker | M | 65 | 6 years | |
| Jia Huey Cheng | F | 48 | 1 years | |
| Lindsay Melvin | M | - | 3 years | |
| Philip Lee | M | 43 | 4 years | |
| Daniel O'Day | M | 59 | 5 years | |
| Alistair Gray | M | 75 | 9 years | |
| Maria Rivas | M | 60 | 2 years | |
| Markus Bamberger | M | 58 | 5 years | |
| Lars Guldbæk Karlsson | M | 63 | 1 years | |
| Philip L. Smith | M | 74 |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | 5 years |
| Meredith Fisher | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 4 years |
| Rehan Verjee | M | 43 | 6 years | |
| Timothy Irish | M | 59 | 5 years | |
| David James Crabb | M | 57 | - | |
| Anne Philomena Hyland | F | 64 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Paul Toon | M | 56 |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | 5 years |
| Karl-Ludwig Kley | M | 72 | 10 years | |
| Joost J. M. Holthuis | M | 71 |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | 14 years |
| Jeremy Randall | M | 60 | 5 years | |
| Thomas Charlton | M | 66 | 14 years | |
| David Chiswell | M | 70 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 4 years |
| Inderpal Singh | M | 58 | 2 years | |
| Andrew Schiermeier | M | 54 | 3 years | |
| David Skok | M | 69 |
University of Sussex
| 4 years |
| Gregor Schulz | M | 74 | 5 years | |
| Oluwatoyin Ashiru | M | 69 |
University of Sussex
| 4 years |
| Tobias Thelen | M | 48 | 5 years | |
| Roy Kevin Halliday | M | - |
University of Sussex
| 4 years |
| Benyamin Subrata | M | 66 |
University of Sussex
| 4 years |
| Shamshad Akhtar | M | 70 |
University of Sussex
| 1 years |
| Mustafa Sani Sener | M | 69 |
University of Sussex
| 1 years |
| Zaborowski MaryJo | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 42 | 42.00% |
| Belgium | 17 | 17.00% |
| Switzerland | 15 | 15.00% |
| Germany | 14 | 14.00% |
| United States | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Simon Sturge
- Personal Network